GlassScriptPhysician profile
Jason K Burrus
NPI 1619935178
$5,204.98
in general payments reported to CMS, 2019-2025
41 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,556 · 2020: $284 · 2021: $241 · 2022: $708 · 2023: $638 · 2024: $1,000 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,152 · Travel and Lodging: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.58 |
| Travel and Lodging | $265.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,133.08 | 2019 | |
| Antares Pharma, INC. | $607.90 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Procept Biorobotics Corporation | $528.83 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Sumitomo Pharma America, INC. | $471.28 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $315.70 | 2019-2025 | |
| Astellas Pharma US INC | $229.43 | 2019-2024 | Myrbetriq, Xtandi |
| Coloplast Corp | $145.07 | 2019-2025 | Speedicath |
| Urovant Sciences INC | $143.97 | 2021-2022 | |
| Urogen Pharma, INC. | $132.93 | 2022-2025 | Jelmyto |
| Verity Pharmaceuticals INC. | $124.18 | 2023-2025 | Trelstar, Tlando |
| Myovant Sciences INC. | $112.24 | 2021-2022 | |
| Allergan, INC. | $105.75 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.67 | 2020-2023 | |
| Immunitybio, INC. | $96.88 | 2025 | |
| Progenics Pharmaceuticals, INC. | $83.10 | 2023-2024 | Pylarify |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $76.49 | 2023-2025 | Eligard, Jatenzo, Rubraca |
| Myriad Genetic Laboratories, INC. | $70.27 | 2021-2024 | Prolaris |
| Endo Pharmaceuticals INC. | $64.25 | 2019-2022 | |
| Olympus America INC. | $59.18 | 2023-2025 | Itind System |
| Abbvie INC. | $59.07 | 2022 | |
| Merck Sharp & Dohme LLC | $49.33 | 2022-2023 | Keytruda, Welireg, Lynparza |
| Halozyme INC | $44.44 | 2023 | |
| Convatec INC. | $43.19 | 2019 | |
| Axonics, INC. | $32.86 | 2023-2024 | Axonics |
| Hollister Incorporated | $32.01 | 2023 | Infyna Chic, Vapro |
| Medtronic, INC. | $31.74 | 2021 | |
| Janssen Biotech, INC. | $31.59 | 2019-2025 | Erleada |
| Mission Pharmacal Company | $30.90 | 2021-2022 | |
| 180 Medical, INC. | $29.96 | 2022 | |
| Dendreon Pharmaceuticals LLC | $27.47 | 2021 | |
| Photocure INC | $24.79 | 2021-2023 | Cysview |
| Rochester Medical Corporation | $23.18 | 2020 | |
| Pharmaand Gmbh | $21.30 | 2025 | Rubraca |
| Tolmar Pharmaceuticals, INC. | $21.25 | 2022 | |
| Cook Medical LLC | $18.96 | 2025 | Cook |
| Cumberland Pharmaceuticals, INC. | $16.48 | 2019 | |
| Boston Scientific Corporation | $14.50 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.01 | 2023 | Seglentis |
| Bard Access Systems, INC. | $13.52 | 2019 | |
| Therapeuticsmd, INC. | $13.10 | 2019 | |
| Travere Therapeutics, INC. | $10.13 | 2020-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Burrus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.